A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
Status:
Recruiting
Trial end date:
2025-10-06
Target enrollment:
Participant gender:
Summary
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved
dose with increases in the infusion rate and reduced infusion volume. This study aims to
generate data to provide the guidance on how infusion rate can be safely increased and
minimize the burden of the life-long treatment with Fabrazyme.